TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05647889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jet lidocaine
Description: Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ice
Description: Ice will be applied for 1 minute before PVC, and then PVC will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVC procedure
Description: Standard PVC procedure will be applied
Study: NCT06524830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLS-01-203 BU
Description: Buccal administration of VLS-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VLS-01-BU Placebo
Description: Buccal administration of VLS-01 Placebo
Study: NCT05587166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guided adductor canal block
Description: ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
Study: NCT05887609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
Study: NCT05159271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Azeol spray nasal
Description: Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
Study: NCT05042531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine, 75mg/m2,d1-7;Treatment cycles every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: dasatinib,20mg,po,qd,treatment cycles every 28 days
Study: NCT05458466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
Study: NCT05147155

Intervention type: BIOLOGICAL
Intervention: Mepolizumab
Description: This will be a 2-year prospective study. Patients with uncontrolled severe asthma will receive mepolizumab according to standard of care and best clinical practice, which will be administered as a 100-mg subcutaneous dose every four weeks.
Study: NCT04217252

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PMseqTM high-throughput sequencing technology
Description: high throughput sequencing of infectious pathogens
Study: NCT05587166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided adductor canal block
Description: ultrasound-guided adductor canal block using oblique short-axis for catheter insertion
Study: NCT05979168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call and text Messages
Description: The intervention consists of recommended lifestyle counselling (on a healthy diet, physical activity, smoking, alcohol intake, medication adherence and continuity of care). This counselling will be provided through the research nurse at baseline and for six months (tentative plan phone call once a month; frequency and duration will be finalized based on formative study) by calling on participants' given mobile numbers. In addition, text message reminders on the same topics will be delivered regularly (2-3 times a week) for six months. The counselling and message will focus on three domains of COM-B; capabilities needed, opportunities and practical tools, and motivation strategies informed by behaviour change techniques.
Study: NCT05277038

Intervention type: DRUG
Intervention: Clonidine 0.1mg pill
Description: Routine prescription for insomnia

Intervention type: DRUG
Intervention: Clonidine 0.2mg pill
Description: Routine prescription for insomnia

Intervention type: DRUG
Intervention: Zopiclone 3.75mg pill
Description: Routine prescription for insomnia

Intervention type: DRUG
Intervention: Zopiclone 7.5mg pill
Description: Routine prescription for insomnia
Study: NCT05568550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be delivered via IV at 200mg on day 1 of each 3-week cycle for approximately 12 months. Cycle 1 begins 21 days prior to radiation therapy and cycles 2-17 are administered during and after radiation therapy.
Study: NCT05284669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental e-learning
Description: Interactive lecture based on the guidelines for the management of LBP with a focus on self-management and patient's reassurance

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional e-learning
Description: Traditional lecture based on the guidelines for the management of LBP with a focus on diagnostic triage and specific cause of LBP
Study: NCT04305340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myant SKIIN Device
Description: 1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myant SKIIN Device
Description: 1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes
Study: NCT05568550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 200mg Olaparib will be given twice daily for a total of 3 cycles. Cycle 1 begins 21-days prior to radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
Study: NCT05568550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Definitive radiation (total dose and fractions) will be dosed per institutional standards. Definitive radiation may include external beam radiation therapy with or without brachytherapy, based on NCCN risk score and as per treating physicians.
Study: NCT05440318

Intervention type: DEVICE
Intervention: Wireless wearable digital devices
Description: Wireless wearable digital devices (including a small patch, modified watch, and datahub smartphone with electronic Patient Reported Outcomes \[ePRO\] capability) will be provided to each participant enrolled in the study.
Study: NCT05477199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral principles-based treatment program
Description: The treatment protocol had a total duration of 6 weeks. Two sessions were conducted each week, the first being a group session lasting 1.5 hours and the second an individual session lasting 45 minutes. During the group sessions, emotional disclosure and sharing of the experiences of patients with post COVID-19 syndrome were encouraged. During the individual sessions, a strong relationship was developed between the patient and the healthcare professional, with the healthcare professional helping the patient develop self-efficacy, thought monitoring, helpful self-talk, and reflection on changes in activity levels throughout the program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Patients received an informational brochure in a consultation with a health professional. The brochure explained the importance of physical activity to improve the health condition of these patients. Patients had the opportunity to ask any questions to the healthcare professional.
Study: NCT05118490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily rifapentine and isoniazid for 4 weeks
Description: Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily rifapentine and isoniazid for 4 weeks
Description: Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly rifapentine and isoniazid for 12 weeks
Description: Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly rifapentine and isoniazid for 12 weeks
Description: Arm B: isoniazid (900mg) and rifapentine (900mg) weekly for 12 weeks (3HP)
Study: NCT05121324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standardized seizure protocol
Description: The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional seizure protocol
Description: The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
Study: NCT06252441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Diclofenac
Description: 100 mg Rectal Diclofenac Before ERCP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral N-acetyl cysteine
Description: 1200 mg N-acetyl cysteine in 150 cc water orally before ERCP.
Study: NCT05823272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS
Description: oral nutritional supplement
Study: NCT04454944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPG subsidy
Description: Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPG subsidy
Description: Different subsidy rates, ranging between 0% and 100% (listed below) will be written on cards. Individuals will randomly select a card to display the subsidy rate for each household. The card will be concealed with a scratch-off sticker, with a higher likelihood of drawing a high price (low subsidy) than a low price (high subsidy) given that take up will be higher in the latter group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance allocation
Description: We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance allocation
Description: We will set up fuel supply depots to increase the convenience and lower costs and hassle associated with traveling to an established filling station. The supply depots will mirror a recirculation model of LPG distribution currently being piloted by the National Petroleum Authority of Ghana. Households will be randomly assigned to one of the supply depots in advance or to continue refilling their cylinder at the filling station.
Study: NCT06020443

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Low Dose chest CT Scan for Lung Cancer Screening
Description: Low dose CT scans will be performed for three years
Study: NCT04714021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2
Description: to insufflate CO2 into the stomach instead of air during the PEG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2
Description: to insufflate CO2 into the stomach instead of air during the PEG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air
Description: to insufflate air into the stomach instead of CO2 during the PEG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air
Description: to insufflate air into the stomach instead of CO2 during the PEG
Study: NCT05288049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing cognitive reserve
Description: The CR enhancement protocol consists of 12 weekly sessions in a group format with audiovisual and technological devices support. All sessions are held separately for parents and children, adolescents and young adults. All material is adapted to different ranges of age. This same protocol will be adapted for patients with a first affective or non-affective episode. Two sessions are about to promote healthy lifestyle by implementing healthy habits, two more sessions about training and practice mindfulness with virtual reality devices, two sessions about improving leisure-time activities, focused on promoting of intellectual and/or cultural activities as leisure time as well as physical exercise, the rest of sessions are about to promote vocational and educational activities, metacognition, social skills, problem-solving techniques and how to detect and act on warning signs, a brief psychoeducative session about the main early warning signs of general psychopathology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support therapy
Description: The support control group will have weekly meetings with assistants to talk about the difficulties they had during the week, without receiving a specific intervention.
Study: NCT05999448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT)
Description: DBT will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Durand Sleep Intervention
Description: Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.
Study: NCT04898036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Therapy
Description: This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Therapy
Description: This phototherapy device (PTD-1) consists of a Plexiglas hand compartment (cleanable) enclosed in a powder-coated steel cabinet. Within the cabinet are two blue LED panels located above and below the hand compartment to illuminate the hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Light Therapy
Description: To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Light Therapy
Description: To turn the device into a sham mode, a thin opaque liner can be inserted which will block light from illuminating the hands.